ClinicalTrials.gg
CompletedNCT05654610Updated Apr 19, 2023

Real-world Evidence Study on the Performance and Safety of Halova Ovules

An observational study in Vaginal Atrophy, sponsored by Perfect Care Distribution. Completed at 14 sites in Romania. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Perfect Care Distribution · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
249
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

An open-label, multicentric, non-randomized, single-arm, pilot, interventional clinical investigation to confirm the tolerability and performance of the medical device Halova in lubrication of the vagina and vaginal atrophy treatment.

Read the detailed description

The primary objective of this investigation is to evaluate the therapeutic performance and tolerability of Halova ovules in treating vaginal atrophy and restoring the natural lubrication of the vaginal mucosa.

The secondary objective of this clinical investigation are to evaluate the performance of the medical device by clinical examination, and the degree of patient satisfaction related to the intended use (Likert scale).

02

Conditions studied

  • Vaginal Atrophy

Browse trials for

Keywords

  • Dyspareunia
  • Dysuria
  • Vaginal lubrication
03

In context

Dyspareunia

158 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

This study's enrollment of 249 is above the median of 165 across 30 observational studies indexed under Dyspareunia.

Browse Dyspareunia studies →

Lead sponsor

Perfect Care Distribution is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult women, with atrophic vaginitis caused by estrogen hormone deficiency or vaginal dryness as a result of contraceptive treatment or other disorders.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women, aged between 18 and above, in pre-menopause or menopause;
  • Adult women with atrophic vaginitis caused by estrogen hormone deficiency;
  • Adult women who have vaginal dryness as a result of treatment or other disorders;
  • Subjects with a normal cervical cytology report, e.g. Negative for intraepithelial lesions or (NILM) or slightly changed to atypical squamous cells of undetermined significance (ASC-US) in the last 6 months;
  • Subjects willing to provide signed for participation in clinical investigation.

Exclusion criteria

Exclusion Criteria:

  • Subjects with vulvar or cervical cancer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
249 participants (actual)
Patient registry
No

Interventions

  • DeviceHalova

    Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.

06

What researchers measure

Primary outcomes

  1. Rating and assessing of treatment-related Adverse Events

    The safety of Halova® ovules as measured by the rate of treatment-related adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation

    Time frame: 30 days

Secondary outcomes

  1. Clinical Performance

    Evaluation by the Investigator of the disorder-related symptoms

    Time frame: 30 days

  2. Patient Satisfaction

    The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale from Very satisfied to Very unsatisfied

    Time frame: 30 days

07

Study locations

14 sites
  • Spitalul Clinic Dr. Ion Cantacuzino Bucharest
    Bucharest, Romania
  • Med Life Humanitas Cluj-Napoca
    Cluj-Napoca, Romania
  • Cabinet Medical - Dr. Saleh K. Majed
    Craiova, Romania
  • Cabinet Medical - Dr. Surpanelu Oana
    Iaşi, Romania
  • MediBlue
    Iaşi, Romania
  • Clinica Natisan Pitesti
    Piteşti, Romania
  • Cabinet Dr. Rădulescu G. Mihaela Elena
    Râmnicu Vâlcea, Romania
  • Ramnicu Valcea
    Râmnicu Vâlcea, Romania
  • Cabinet Ginecologic Dr. Popescu Sibiu
    Sibiu, Romania
  • Clinica iMED
    Sibiu, Romania
  • Pan Medical Sibiu
    Sibiu, Romania
  • Clinica Medicala Dr. Cioata Ionel Trifon
    Timişoara, Romania
  • Spitalul Judetean de Urgenta Tulcea
    Tulcea, Romania
  • Bradmed SRL
    Târgu Jiu, Romania
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05654610
Lead sponsor
Perfect Care Distribution
Collaborators
MDX Research
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Mar 1, 2022
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Apr 19, 2023

Study contacts

Ema Peta
study director · Perfect Care Distribution

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion